Anti-ILT4 antibodies and antigen-binding fragments

US11897956B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Agenus Inc. · US

Inventors

• Milan Blanusa · Jena, DE
• Barbara Joyce-Shaikh · San Jose, US
• Andrea Schuster · Bayreuth, DE
• Kornelia Schultze · Jena, DE
• Luis A. Zuniga · Mountain View, US

Key dates

• Filing date: Jun 3, 2021
• Grant date: Feb 13, 2024
• Expiry date: Feb 22, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.